Fatty acid–binding protein 4 (FABP4) is a possible biomarker of atherosclerosis. We evaluated FABP4 levels, for the first time, in patients with peripheral artery disease (PAD) and the possible association between baseline FABP4 levels and cardiovascular events over time. Patients (n = 327; mean age 69 ± 10 years) with stable PAD were enrolled in this study. Serum FABP4 was measured by bead-based multiplex assay. Cardiovascular events were analyzed by FABP4 tertiles using Kaplan-Meier and Cox regression analyses after 5 years. Serum FABP4 levels showed a significant association with the classical 3-point major adverse cardiovascular event (MACE) end point (including death, nonlethal myocardial infarction, or nonfatal stroke) in patients with PAD (P = .038). A standard deviation increase of FABP4 resulted in a hazard ratio (HR) of 1.33 (95% confidence interval [95% CI]: 1.03-1.71) for MACE. This association increased (HR: 1.47, 95% CI: 1.03-1.71) after multivariable adjustment (P = .020). Additionally, in multivariable linear regression analysis, FABP4 was linked to estimated glomerular filtration rate (P < .001), gender (P = .005), fasting triglycerides (P = .048), and body mass index (P < .001). Circulating FABP4 may be a useful additional biomarker to evaluate patients with stable PAD at risk of major cardiovascular complications.
XuHBarnesGTYangQ. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112(12):1821–1830.
4.
BartholomewJROlinJW. Pathophysiology of peripheral arterial disease and risk factors for its development. Cleve Clinic J Med. 2006;73(suppl 4):S8–S14.
5.
NorgrenLHiattWRDormandyJA. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33(suppl 1):S1–S75.
6.
WiviottSDCannonCPMorrowDA. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol. 2005;46(8):1411–1416.
7.
BaigentCKeechAKearneyPM. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–1278.
8.
CatapanoALGrahamIDe BackerG. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999–3058.
9.
TrayhurnPWoodIS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004;92(3):347–355.
10.
XuAWangYXuJY. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem. 2006;52(3):405–413.
11.
FuruhashiMFuchoRGorgunCZTuncmanGCaoHHotamisligilGS. Adipocyte/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice. J Clin Invest. 2008;118(7):2640–2650.
12.
KralischSFasshauerM. Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease?Diabetologia. 2013;56(1):10–21.
13.
MakowskiLBoordJBMaedaK. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nature Med. 2001;7(6):699–705.
14.
FuruhashiMTuncmanGGorgunCZ. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature. 2007;447(7147):959–965.
15.
MiyoshiTOnoueGHirohataA. Serum adipocyte fatty acid-binding protein is independently associated with coronary atherosclerotic burden measured by intravascular ultrasound. Atherosclerosis. 2010;211(1):164–169.
16.
RheeEJLeeWYParkCY. The association of serum adipocyte fatty acid-binding protein with coronary artery disease in Korean adults. Eur J Endocrinol. 2009;160(2):165–172.
17.
YeungDCXuACheungCW. Serum adipocyte fatty acid-binding protein levels were independently associated with carotid atherosclerosis. Arterioscler ThrombVasc Biol. 2007;27(8):1796–1802.
18.
ReiserHKlingenbergRHofD. Circulating FABP4 is a prognostic biomarker in patients with acute coronary syndrome but not in asymptomatic individuals. Arterioscler Thromb Vasc Biol. 2015;35(8):1872–1879.
19.
HobausCHerzCTObendorfF. Center-based patient care enhances survival of elderly patients suffering from peripheral arterial disease. Ann Med. 2017;49(4):291–298.
European Parliament. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. 2001. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:32001L0020:EN:NOT. Accessed October 19, 2017.
22.
ManciaGFagardRNarkiewiczK. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159–2219.
23.
Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003;26(suppl 1):S5–S20.
24.
LeveyASStevensLASchmidCH. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612.
25.
CockcroftDWGaultMH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.
26.
DoiMMiyoshiTHirohataS. Association of increased plasma adipocyte fatty acid-binding protein with coronary artery disease in non-elderly men. Cardiovasc Diabetol. 2011;10:44.
27.
ChowWSTsoAWXuA. Elevated circulating adipocyte-fatty acid binding protein levels predict incident cardiovascular events in a community-based cohort: a 12-year prospective study. J Am Heart Assoc. 2013;2(1):e004176.
28.
von EynattenMBreitlingLPRoosMBaumannMRothenbacherDBrennerH. Circulating adipocyte fatty acid-binding protein levels and cardiovascular morbidity and mortality in patients with coronary heart disease: a 10-year prospective study. Arterioscler Thromb Vasc Biol. 2012;32(9):2327–2335.
29.
FuruhashiMIshimuraSOtaH. Serum fatty acid-binding protein 4 is a predictor of cardiovascular events in end-stage renal disease. PLoS One. 2011;6(11):e27356.
30.
FuruhashiMSaitohSShimamotoKMiuraT. Fatty acid-binding protein 4 (FABP4): pathophysiological insights and potent clinical biomarker of metabolic and cardiovascular diseases. Clin Med Insights Cardiol. 2014;8(suppl 3):23–33.
31.
StejskalDKarpisekM. Adipocyte fatty acid binding protein in a Caucasian population: a new marker of metabolic syndrome?Eur J Clin Invest. 2006;36(9):621–625.
32.
TsoAWXuAShamPC. Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: a 10-year prospective study in a Chinese cohort. Diabetes Care. 2007;30(10):2667–2672.
33.
CabreALazaroIGironaJ. Plasma fatty acid-binding protein 4 increases with renal dysfunction in type 2 diabetic patients without microalbuminuria. Clin Chem. 2008;54(1):181–187.
